Novel compound useful for the treatment of degenerative and inflammatory diseases

Patent metadata

Field	Value
Publication number	US-2020078365-A1
Application number	US-201916407593-A
Country	US
Kind code	A1
Filing date	May 9, 2019
Priority date	Jun 26, 2009
Publication date	Mar 12, 2020
Grant date	—

Abstract

A novel compound able to inhibit JAK is disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.

First claim

1 . A compound according to Formula I:

or a pharmaceutically acceptable salt thereof.

2 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according claim 1 .

3 . The pharmaceutical composition according to claim 2 comprising a further therapeutic agent.

4 . (canceled)

5 . (canceled)

6 . (canceled)

7 . (canceled)

8 . A method for the treatment, prevention or prophylaxis of inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6, comprising administering an amount of a compound of claim 1 , sufficient to effect said treatment, prevention or prophylaxis.

9 . The method according to claim 8 , comprising administering a further therapeutic agent.

10 . The method according to claim 9 , wherein the further therapeutic agent is an agent for the treatment, prevention or prophylaxis of inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.

11 . The method of claim 8 , wherein the autoimmune disease is obstructive airway disease, COPD, asthma, bronchitis, systemic lupus erythematosus, multiple sclerosis, type I diabetes mellitus, atopic eczema, contact dermatitis and further eczematous dermatitis, inflammatory bowel disease, atherosclerosis and amyotrophic lateral sclerosis.

12 . The method of claim 11 , wherein the autoimmune disease is systemic lupus erythematosus.

13 . A method for the treatment, prevention or prophylaxis of inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6, comprising administering an amount of a pharmaceutical composition of claim 2 , sufficient to effect said treatment, prevention or prophylaxis.

14 . The method of claim 13 , wherein the autoimmune disease is obstructive airway disease, COPD, asthma, bronchitis, systemic lupus erythematosus, multiple sclerosis, type I diabetes mellitus and complications associated therewith, atopic eczema, contact dermatitis and further eczematous dermatitis, inflammatory bowel disease, atherosclerosis and amyotrophic lateral sclerosis.

15 . The method of claim 14 , wherein the autoimmune disease is systemic lupus erythematosus.

16 . The method according to claim 13 , comprising administering a further therapeutic agent.

17 . The method according to claim 16 , wherein the further therapeutic agent is an agent for the treatment, prevention or prophylaxis of inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.

18 . A method for the treatment, prevention or prophylaxis of inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6, comprising administering an amount of a pharmaceutical composition of claim 3 , sufficient to effect said treatment, prevention or prophylaxis.

19 . The method of claim 18 , wherein the autoimmune disease is obstructive airway disease, COPD, asthma, bronchitis, systemic lupus erythematosus, multiple sclerosis, type I diabetes mellitus and complications associated therewith, atopic eczema, contact dermatitis and further eczematous dermatitis, inflammatory bowel disease, atherosclerosis and amyotrophic lateral sclerosis.

20 . The method of claim 19 , wherein the autoimmune disease is systemic lupus erythematosus.

21 . The method according to claim 18 , wherein the further therapeutic agent is an agent for the treatment, prevention or prophylaxis of inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.

Assignees

• Galapagos Nv

Inventors

• Menet Christel Jeanne Marie
• Smits Koen Kurt

Classifications

• A61P37/02

  Immunomodulators · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title